MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

Search

BioCryst Pharmaceuticals Inc

Abierto

SectorSanidad

8.58 -1.61

Resumen

Variación precio

24h

Actual

Mínimo

8.53

Máximo

8.79

Métricas clave

By Trading Economics

Ingresos

27M

32K

Ventas

14M

146M

Margen de beneficios

0.022

Empleados

580

EBITDA

22M

21M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+86.94% upside

Dividendos

By Dow Jones

Próximas Ganancias

4 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

23M

1.9B

Apertura anterior

10.19

Cierre anterior

8.58

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

154 / 376 Clasificación en Healthcare

BioCryst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

15 jul 2025, 23:41 UTC

Charlas de Mercado

Nikkei May Trade in Range Amid Tariff Uncertainty -- Market Talk

15 jul 2025, 23:40 UTC

Charlas de Mercado

Gold Edges Higher on Possible Position Adjustments -- Market Talk

15 jul 2025, 23:05 UTC

Charlas de Mercado

Auckland International Airport Passenger Growth May Disappoint Again -- Market Talk

15 jul 2025, 21:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 jul 2025, 21:36 UTC

Charlas de Mercado

Canada CPI Data Fuel Rate-Prediction Revisions -- Market Talk

15 jul 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

15 jul 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

15 jul 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 jul 2025, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

15 jul 2025, 20:14 UTC

Adquisiciones, fusiones, absorciones

Chinese EV Makers to Combine. Geely Is Buying Zeekr. -- Barrons.com

15 jul 2025, 20:07 UTC

Ganancias

BlackRock Shares Tumble After Big Client Redemption Blunts Quarterly Results -- Update

15 jul 2025, 20:06 UTC

Charlas de Mercado

Nvidia, AMD Seen Benefiting from Return to Chinese Chip Sales -- Market Talk

15 jul 2025, 19:54 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

15 jul 2025, 19:54 UTC

Charlas de Mercado

Meta CEO Hints at Higher Revenues, Expenses With Data Center Plans -- Market Talk

15 jul 2025, 19:38 UTC

Charlas de Mercado

Oil Falls As Eventual Oversupply Concerns Weigh -- Market Talk

15 jul 2025, 19:09 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Back-to-Back Gains -- Market Talk

15 jul 2025, 19:07 UTC

Charlas de Mercado

Canada CFOs Willing to Take Risks, Increase Spending -- Market Talk

15 jul 2025, 19:03 UTC

Charlas de Mercado

Gold Slips as Big Buyers Pull Back -- Market Talk

15 jul 2025, 18:32 UTC

Adquisiciones, fusiones, absorciones

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 jul 2025, 18:31 UTC

Adquisiciones, fusiones, absorciones

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

15 jul 2025, 18:13 UTC

Charlas de Mercado

Canada Adopts 'Note of Realism' in US Trade Talks, Setting Stage for Possible Tariff Deal -- Market Talk

15 jul 2025, 17:40 UTC

Charlas de Mercado

Canadian Inflation Adds to Case for Bank of Canada Extending Pause -- Market Talk

15 jul 2025, 17:40 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 jul 2025, 17:25 UTC

Adquisiciones, fusiones, absorciones

National Fuel Gas Gets Rare Double Upgrade. Buy the Stock, Analyst Says. -- Barrons.com

15 jul 2025, 17:24 UTC

Charlas de Mercado

Dollar Gains Strength After Inflation Data -- Market Talk

15 jul 2025, 16:49 UTC

Charlas de Mercado

Oil Futures Likely to Continue Sideways Trade -- Market Talk

15 jul 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

15 jul 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 jul 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

15 jul 2025, 15:42 UTC

Charlas de Mercado

Coca-Cola Seen as Top Pick Ahead of Consumer Staples Earnings -- Market Talk

Comparación entre iguales

Cambio de precio

BioCryst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

86.94% repunte

Estimación a 12 Meses

Media 16.75 USD  86.94%

Máximo 30 USD

Mínimo 11 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioCryst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

11

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

154 / 376 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.